Home > Cardiology > ACC/WCC 2020 > Atrial Fibrillation/Acute Coronary Syndrome > TWILIGHT sub-study: same outcomes for diabetes patients

TWILIGHT sub-study: same outcomes for diabetes patients

Presented By
Prof. D. Angiolillo, University of Florida - Jacksonville, USA
Conference
ACC 2020
Trial
TWILIGHT, TWILIGHT-DM
A pre-specified sub-analysis of the TWILIGHT trial demonstrated that participants with diabetes mellitus (DM) who had had a recent percutaneous coronary intervention (PCI) did not differ in death, myocardial infarction (MI), or stroke between the arms (i.e. ticagrelor with either aspirin or placebo) when compared with participants who were not diabetic. The parent TWILIGHT trial took patients who had just undergone PCI and treated them with ticagrelor plus aspirin for 3 months and, if event-free and adherent, randomly assigned them to ticagrelor plus aspirin or plus placebo for an additional 12 months. The main conclusion of that trial was that dropping aspirin after 3 months of dual antiplatelet therapy (DAPT) following PCI among high-risk patients was ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on